These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 29551288)

  • 1. Ranking Enzyme Structures in the PDB by Bound Ligand Similarity to Biological Substrates.
    Tyzack JD; Fernando L; Ribeiro AJM; Borkakoti N; Thornton JM
    Structure; 2018 Apr; 26(4):565-571.e3. PubMed ID: 29551288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure and mechanistic implications of a uroporphyrinogen III synthase-product complex.
    Schubert HL; Phillips JD; Heroux A; Hill CP
    Biochemistry; 2008 Aug; 47(33):8648-55. PubMed ID: 18651750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Segment swapping aided the evolution of enzyme function: The case of uroporphyrinogen III synthase.
    Szilágyi A; Györffy D; Závodszky P
    Proteins; 2017 Jan; 85(1):46-53. PubMed ID: 27756106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studying enzyme binding specificity in acetylcholinesterase using a combined molecular dynamics and multiple docking approach.
    Kua J; Zhang Y; McCammon JA
    J Am Chem Soc; 2002 Jul; 124(28):8260-7. PubMed ID: 12105904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for an intermediate in the enzymatic formation of uroporphyrinogen III.
    Pichon C; Atshaves BP; Stolowich NJ; Scott AI
    Bioorg Med Chem; 1994 Mar; 2(3):153-68. PubMed ID: 7922129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studying the roles of W86, E202, and Y337 in binding of acetylcholine to acetylcholinesterase using a combined molecular dynamics and multiple docking approach.
    Kua J; Zhang Y; Eslami AC; Butler JR; McCammon JA
    Protein Sci; 2003 Dec; 12(12):2675-84. PubMed ID: 14627729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three-Dimensional Biologically Relevant Spectrum (BRS-3D): Shape Similarity Profile Based on PDB Ligands as Molecular Descriptors.
    Hu B; Kuang ZK; Feng SY; Wang D; He SB; Kong DX
    Molecules; 2016 Nov; 21(11):. PubMed ID: 27869685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cognate ligand domain mapping for enzymes.
    Bashton M; Nobeli I; Thornton JM
    J Mol Biol; 2006 Dec; 364(4):836-52. PubMed ID: 17034815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Choosing the Best Enzyme Complex Structure Made Easy.
    Das S; Orengo C
    Structure; 2018 Apr; 26(4):528-530. PubMed ID: 29617649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Knowledge-guided docking: accurate prospective prediction of bound configurations of novel ligands using Surflex-Dock.
    Cleves AE; Jain AN
    J Comput Aided Mol Des; 2015 Jun; 29(6):485-509. PubMed ID: 25940276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pose prediction approach based on ligand 3D shape similarity.
    Kumar A; Zhang KY
    J Comput Aided Mol Des; 2016 Jun; 30(6):457-69. PubMed ID: 27379501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonlinear scoring functions for similarity-based ligand docking and binding affinity prediction.
    Brylinski M
    J Chem Inf Model; 2013 Nov; 53(11):3097-112. PubMed ID: 24171431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening of drug target proteins by 2D ligand matching approach.
    Feng J; Guo H; Wang J; Lu T
    Chem Biol Drug Des; 2014 Feb; 83(2):174-82. PubMed ID: 24034065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of 3D-QSAR Model for Acetylcholinesterase Inhibitors Using a Combination of Fingerprint, Molecular Docking, and Structure-Based Pharmacophore Approaches.
    Lee S; Barron MG
    Toxicol Sci; 2015 Nov; 148(1):60-70. PubMed ID: 26202430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The evidence for a spirocyclic intermediate in the formation of uroporphyrinogen III by cosynthase.
    Leeper FJ
    Ciba Found Symp; 1994; 180():111-23; discussion 124-30. PubMed ID: 7842849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Binding mode similarity measures for ranking of docking poses: a case study on the adenosine A2A receptor.
    Anighoro A; Bajorath J
    J Comput Aided Mol Des; 2016 Jun; 30(6):447-56. PubMed ID: 27334985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The discovery of new acetylcholinesterase inhibitors derived from pharmacophore modeling, virtual screening, docking simulation and bioassays.
    Zhang Y; Zhang S; Xu G; Yan H; Pu Y; Zuo Z
    Mol Biosyst; 2016 Nov; 12(12):3734-3742. PubMed ID: 27801451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preuroporphyrinogen, a universal intermediate in the biosynthesis of uroporphyrinogen III.
    Jordan PM; Berry A
    FEBS Lett; 1980 Mar; 112(1):86-8. PubMed ID: 6989639
    [No Abstract]   [Full Text] [Related]  

  • 19. Purification and properties of uroporphyrinogen III synthase (co-synthetase) from Euglena gracilis.
    Hart GJ; Battersby AR
    Biochem J; 1985 Nov; 232(1):151-60. PubMed ID: 3936481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A steric blockade model for inhibition of acetylcholinesterase by peripheral site ligands and substrate.
    Rosenberry TL; Mallender WD; Thomas PJ; Szegletes T
    Chem Biol Interact; 1999 May; 119-120():85-97. PubMed ID: 10421442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.